

Lanfranco Fattorini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7981850/publications.pdf>

Version: 2024-02-01

105
papers

4,274
citations

109137

35
h-index

123241

61
g-index

106
all docs

106
docs citations

106
times ranked

5110
citing authors

#	ARTICLE	IF	CITATIONS
1	Activity of Drug Combinations against <i>Mycobacterium abscessus</i> Grown in Aerobic and Hypoxic Conditions. <i>Microorganisms</i> , 2022, 10, 1421.	1.6	4
2	Moxifloxacin Activates the SOS Response in <i>Mycobacterium tuberculosis</i> in a Dose- and Time-Dependent Manner. <i>Microorganisms</i> , 2021, 9, 255.	1.6	13
3	The Antimalarial Mefloquine Shows Activity against <i>Mycobacterium abscessus</i> , Inhibiting Mycolic Acid Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8533.	1.8	4
4	<i>Mycobacterium tuberculosis</i> and SARS-CoV-2 Coinfections: A Review. <i>Frontiers in Microbiology</i> , 2021, 12, 747827.	1.5	11
5	Drug-Resistant Tuberculosis 2020: Where We Stand. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2153.	1.3	46
6	Bacterial coinfections in COVID-19: an underestimated adversary. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2020, 56, 359-364.	0.2	55
7	The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant <i>Mycobacterium tuberculosis</i> in Hypoxia at Neutral pH. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	13
8	A Rapid Unraveling of the Activity and Antibiotic Susceptibility of <i>Mycobacteria</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	23
9	Revisiting problems and solutions to decrease <i>Mycobacterium tuberculosis</i> pyrazinamide false resistance when using the Bactec MGIT 960 system. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2019, 55, 51-54.	0.2	4
10	Use of probiotics in medical devices applied to some common pathologies. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2019, 55, 380-385.	0.2	3
11	Trends in the discovery of new drugs for <i>Mycobacterium tuberculosis</i> therapy with a glance at resistance. <i>Tuberculosis</i> , 2018, 109, 17-27.	0.8	47
12	Activity of DNA-targeted C8-linked pyrrolobenzodiazepine-heterocyclic polyamide conjugates against aerobically and hypoxically grown <i>Mycobacterium tuberculosis</i> under acidic and neutral conditions. <i>Journal of Antibiotics</i> , 2018, 71, 831-834.	1.0	3
13	Clofazimine: A useful antibiotic for drug-resistant tuberculosis. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 1353-1359.	2.5	48
14	Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016. <i>European Respiratory Journal</i> , 2018, 52, 1800070.	3.1	16
15	Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries. <i>European Respiratory Journal</i> , 2017, 49, 1602242.	3.1	11
16	<i>Mycobacterium tuberculosis</i> Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	25
17	Improved Bactec MGIT 960 Pyrazinamide Test Decreases Detection of False <i>Mycobacterium tuberculosis</i> Pyrazinamide Resistance. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3552-3553.	1.8	4
18	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 380-392.	0.4	26

#	ARTICLE	IF	CITATIONS
19	Fighting tuberculosis by drugs targeting nonreplicating <i>Mycobacterium tuberculosis</i> bacilli. <i>International Journal of Mycobacteriology</i> , 2017, 6, 213.	0.3	29
20	External Quality Assessment for Tuberculosis Diagnosis and Drug Resistance in the European Union: A Five Year Multicentre Implementation Study. <i>PLoS ONE</i> , 2016, 11, e0152926.	1.1	25
21	Activity of drugs against dormant <i>Mycobacterium tuberculosis</i> . <i>International Journal of Mycobacteriology</i> , 2016, 5, S94-S95.	0.3	11
22	Pyrazinamide susceptibility testing: proposed new standard with the BACTEC MGIT 960 system. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1677-1680.	0.6	4
23	<i>Mycobacterium tuberculosis</i> gene expression at different stages of hypoxia-induced dormancy and upon resuscitation. <i>Journal of Microbiology</i> , 2016, 54, 565-572.	1.3	55
24	Tuberculosis in migrants from 106 countries to Italy, 2008-2014. <i>European Respiratory Journal</i> , 2016, 47, 1273-1276.	3.1	12
25	Drug-resistant tuberculosis in Naples, 2008-2013. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2016, 52, 603-607.	0.2	2
26	Activity of lipophilic and hydrophilic drugs against dormant and replicating <i>Mycobacterium tuberculosis</i> . <i>Journal of Antibiotics</i> , 2015, 68, 711-714.	1.0	61
27	Towards tuberculosis elimination: an action framework for low-incidence countries. <i>European Respiratory Journal</i> , 2015, 45, 928-952.	3.1	608
28	Rifampin Induces Hydroxyl Radical Formation in <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7527-7533.	1.4	91
29	Risk Factors for Tuberculosis in Foreign-Born People (FBP) in Italy: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e94728.	1.1	19
30	Activities of Drug Combinations against <i>Mycobacterium tuberculosis</i> Grown in Aerobic and Hypoxic Acidic Conditions. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1428-1433.	1.4	61
31	Prevention of False Resistance Results Obtained in Testing the Susceptibility of <i>Mycobacterium tuberculosis</i> to Pyrazinamide with the Bactec MGIT 960 System Using a Reduced Inoculum. <i>Journal of Clinical Microbiology</i> , 2013, 51, 291-294.	1.8	58
32	Whole Genome Sequencing Reveals Complex Evolution Patterns of Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Beijing Strains in Patients. <i>PLoS ONE</i> , 2013, 8, e82551.	1.1	117
33	TARGETING DORMANT BACILLI TO FIGHT TUBERCULOSIS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013072.	0.5	38
34	Drug-resistant tuberculosis among foreign-born persons in Italy: Table 1. <i>European Respiratory Journal</i> , 2012, 40, 497-500.	3.1	20
35	Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy: Figure 1. <i>European Respiratory Journal</i> , 2012, 39, 1263-1266.	3.1	10
36	GenoType MTBDR performance on clinical samples with diverse genetic background. <i>European Respiratory Journal</i> , 2012, 40, 690-698.	3.1	37

#	ARTICLE	IF	CITATIONS
37	Infection of human THP-1 cells with dormant <i>Mycobacterium tuberculosis</i> . <i>Microbes and Infection</i> , 2012, 14, 959-967.	1.0	31
38	Treatment of Tuberculosis in a Region with High Drug Resistance: Outcomes, Drug Resistance Amplification and Re-Infection. <i>PLoS ONE</i> , 2011, 6, e23081.	1.1	26
39	Activity of Drugs Against Dormant <i>Mycobacterium tuberculosis</i> . <i>Journal of Chemotherapy</i> , 2011, 23, 175-178.	0.7	4
40	Expression of Proinflammatory and Regulatory Cytokines via NF- κ B and MAPK-Dependent and IFN Regulatory Factor-3-Independent Mechanisms in Human Primary Monocytes Infected by <i>Mycobacterium tuberculosis</i> . <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-8.	3.3	14
41	Activity of Drug Combinations against Dormant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2712-2715.	1.4	34
42	<i>Mycobacterium tuberculosis</i> Strains with Highly Discordant Rifampin Susceptibility Test Results. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3501-3506.	1.8	167
43	IFN- γ improves BCG immunogenicity by acting on DC maturation. <i>Journal of Leukocyte Biology</i> , 2009, 85, 462-468.	1.5	39
44	The <i>Mycobacterium tuberculosis</i> Sigma Factor σ^B Is Required for Full Response to Cell Envelope Stress and Hypoxia In Vitro, but It Is Dispensable for In Vivo Growth. <i>Journal of Bacteriology</i> , 2009, 191, 5628-5633.	1.0	66
45	Characteristics of drug-resistant tuberculosis in Abkhazia (Georgia), a high-prevalence area in Eastern Europe. <i>Tuberculosis</i> , 2009, 89, 317-324.	0.8	38
46	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. <i>European Respiratory Journal</i> , 2008, 31, 1155-1159.	3.1	131
47	The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against <i>Mycobacterium tuberculosis</i> infection by dampening IFN- γ response. <i>Vaccine</i> , 2008, 26, 4237-4243.	1.7	29
48	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. <i>Clinical Infectious Diseases</i> , 2008, 46, 958-959.	2.9	35
49	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2008, 31, 904-905.	3.1	67
50	Clinical and operational value of the extensively drug-resistant tuberculosis definition. <i>European Respiratory Journal</i> , 2007, 30, 623-626.	3.1	179
51	Pyrazinamide Resistance in Multidrug-Resistant Strains of <i>Mycobacterium tuberculosis</i> Isolated in Abkhazia. <i>Journal of Chemotherapy</i> , 2007, 19, 106-107.	0.7	1
52	Metronidazole plus Rifampin Sterilizes Long-Term Dormant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1537-1540.	1.4	26
53	Isolation of <i>Nocardia asiatica</i> from Cutaneous Ulcers of a Human Immunodeficiency Virus-Infected Patient in Italy. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2088-2089.	1.8	17
54	Usefulness of the BACTEC MGIT 960 System for Isolation of <i>Mycobacterium tuberculosis</i> from Sputa Subjected to Long-Term Storage. <i>Journal of Clinical Microbiology</i> , 2007, 45, 575-576.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxacin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 283-287.	0.8	8
56	The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice. <i>Cellular Microbiology</i> , 2007, 9, 1455-1465.	1.1	38
57	Immune response and protection by DNA vaccines expressing antigen 85B of Mycobacterium tuberculosis. <i>FEMS Microbiology Letters</i> , 2006, 262, 210-215.	0.7	9
58	Infection of Human Dendritic Cells with a Mycobacterium tuberculosis sigE Mutant Stimulates Production of High Levels of Interleukin-10 but Low Levels of CXCL10: Impact on the T-Cell Response. <i>Infection and Immunity</i> , 2006, 74, 3296-3304.	1.0	24
59	Evaluation of Molecular-Beacon, TaqMan, and Fluorescence Resonance Energy Transfer Probes for Detection of Antibiotic Resistance-Confering Single Nucleotide Polymorphisms in Mixed Mycobacterium tuberculosis DNA Extracts. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3826-3829.	1.8	28
60	<i>Mycobacterium tuberculosis</i> Drug Resistance, Abkhazia. <i>Emerging Infectious Diseases</i> , 2005, 11, 501-503.	2.0	12
61	Evaluation of a New Line Probe Assay for Rapid Identification of gyrA Mutations in Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2928-2933.	1.4	49
62	Cetyl-Pyridinium Chloride Is Useful for Isolation of Mycobacterium tuberculosis from Sputa Subjected to Long-Term Storage. <i>Journal of Clinical Microbiology</i> , 2005, 43, 442-444.	1.8	33
63	Drug Resistance Evolution of a Mycobacterium tuberculosis Strain from a Noncompliant Patient. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3114-3120.	1.8	45
64	Mycobacterium bovis Bacillus Calmette-Guerin infects DC-SIGN- dendritic cell and causes the inhibition of IL-12 and the enhancement of IL-10 production. <i>Journal of Leukocyte Biology</i> , 2005, 78, 106-113.	1.5	51
65	A Pyrosequencing assay for rapid recognition of SNPs in Mycobacterium tuberculosis embB306 region. <i>Journal of Microbiological Methods</i> , 2005, 62, 113-120.	0.7	38
66	Mycobacterium tuberculosis Complex Drug Resistance in Italy. <i>Emerging Infectious Diseases</i> , 2004, 10, 752-753.	2.0	7
67	Inhibition of HIV-1 Replication in Monocyte-Derived Macrophages by Mycobacterium tuberculosis. <i>Journal of Infectious Diseases</i> , 2004, 189, 624-633.	1.9	39
68	The Extra Cytoplasmic Function Sigma Factor σ^E Is Essential for Mycobacterium tuberculosis Virulence in Mice. <i>Infection and Immunity</i> , 2004, 72, 3038-3041.	1.0	90
69	Mycobacterium tuberculosis Diverts Alpha Interferon-Induced Monocyte Differentiation from Dendritic Cells into Immunoprivileged Macrophage-Like Host Cells. <i>Infection and Immunity</i> , 2004, 72, 4385-4392.	1.0	48
70	Induction of Mycobacterium avium proteins upon infection of human macrophages. <i>Proteomics</i> , 2004, 4, 3078-3083.	1.3	12
71	In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. <i>Peptides</i> , 2004, 25, 1075-1077.	1.2	56
72	Bacillus Calmette-Guérin shares with virulent the capacity to subvert monocyte differentiation into dendritic cell: implication for its efficacy as a vaccine preventing tuberculosis. <i>Vaccine</i> , 2004, 22, 3848-3857.	1.7	28

#	ARTICLE	IF	CITATIONS
73	Activities of Moxifloxacin Alone and in Combination with Other Antimicrobial Agents against Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Infection in BALB/c Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 360-362.	1.4	51
74	Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000. <i>European Respiratory Journal</i> , 2003, 21, 129-134.	3.1	12
75	An Anti-Inflammatory Role for $V\alpha 14$ NK T cells in <i>Mycobacterium bovis</i> /Bacillus Calmette-Guèrin-Infected Mice. <i>Journal of Immunology</i> , 2003, 171, 1961-1968.	0.4	61
76	<i>Mycobacterium tuberculosis</i> subverts the differentiation of human monocytes into dendritic cells. <i>European Journal of Immunology</i> , 2002, 32, 3050-3058.	1.6	79
77	Recombinant GroES in combination with CpG oligodeoxynucleotides protects mice against <i>Mycobacterium avium</i> infection. <i>Journal of Medical Microbiology</i> , 2002, 51, 1071-1079.	0.7	7
78	Exposure of BALB/c mice to low doses of <i>Mycobacterium avium</i> increases resistance to a subsequent high-dose infection. <i>Microbiology (United Kingdom)</i> , 2002, 148, 3173-3181.	0.7	3
79	Involvement of the <i>fadD33</i> gene in the growth of <i>Mycobacterium tuberculosis</i> in the liver of BALB/c mice. <i>Microbiology (United Kingdom)</i> , 2002, 148, 3873-3880.	0.7	32
80	Infection of Human Macrophages and Dendritic Cells with <i>Mycobacterium tuberculosis</i> Induces a Differential Cytokine Gene Expression That Modulates T Cell Response. <i>Journal of Immunology</i> , 2001, 166, 7033-7041.	0.4	378
81	<i>Bacillus Calmette-Guèrin</i> Down-Regulates CD1b Induction by Granulocyte-Macrophage Colony Stimulating Factor in Human Peripheral Blood Monocytes. <i>Journal of Chemotherapy</i> , 2001, 13, 52-58.	0.7	9
82	Influence of <i>Mycobacterium bovis</i> Bacillus Calmette Guèrin on In Vitro Induction of CD1 Molecules in Human Adherent Mononuclear Cells. <i>Infection and Immunity</i> , 2001, 69, 7461-7470.	1.0	21
83	Virulence and drug susceptibility of <i>Mycobacterium celatum</i> . <i>Microbiology (United Kingdom)</i> , 2000, 146, 2733-2742.	0.7	17
84	<i>Mycobacterium avium</i> infection in BALB/c and SCID mice. <i>Journal of Medical Microbiology</i> , 1999, 48, 577-583.	0.7	4
85	Activity of 16 Antimicrobial Agents Against Drug-Resistant Strains of <i>Mycobacterium tuberculosis</i> . <i>Microbial Drug Resistance</i> , 1999, 5, 265-270.	0.9	33
86	Activities of Eighteen Antimicrobial Regimens against <i>Mycobacterium avium</i> Infection in Beige Mice. <i>Microbial Drug Resistance</i> , 1999, 5, 227-233.	0.9	2
87	Upregulation of p75 Tumor Necrosis Factor Alpha Receptor in <i>Mycobacterium avium</i> -Infected Mice: Evidence for a Functional Role. <i>Infection and Immunity</i> , 1999, 67, 5762-5767.	1.0	13
88	Activities of Isoniazid Alone and in Combination with Other Drugs against <i>Mycobacterium avium</i> Infection in Beige Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 712-714.	1.4	9
89	Non-inducible, mainly cell-associated beta-lactamase from <i>Nocardia asteroides</i> strain 108. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 5-11.	1.3	7
90	Type Frequency and Antimicrobial Susceptibility of <i>Mycobacterium avium</i> -intracellulare Complex Strains Isolated in Italy from AIDS and Non-AIDS Patients. <i>Journal of Chemotherapy</i> , 1996, 8, 37-42.	0.7	20

#	ARTICLE	IF	CITATIONS
91	Late Acquisition of Hyporesponsiveness to Lipopolysaccharide by Mycobacterium avium-Infected Human Macrophages in Producing Tumor Necrosis Factor- α but Not Interleukin- 1α and -6. Journal of Infectious Diseases, 1996, 173, 1030-1034.	1.9	7
92	In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. Antimicrobial Agents and Chemotherapy, 1995, 39, 680-685.	1.4	34
93	Antigenic properties and immunoelectron microscopic localization of Mycobacterium fortuitum beta-lactamase. Antimicrobial Agents and Chemotherapy, 1995, 39, 739-745.	1.4	21
94	Identification of Mycobacterium tuberculosis complex, Mycobacterium avium and Mycobacterium intracellulare by selective nested polymerase chain reaction. Molecular and Cellular Probes, 1995, 9, 321-326.	0.9	12
95	Induction of IL- 1α , IL-6, TNF- α , GM-CSF and G-CSF in human macrophages by smooth transparent and smooth opaque colonial variants of Mycobacterium avium. Journal of Medical Microbiology, 1994, 40, 129-133.	0.7	44
96	Use of the chromosomal class A beta-lactamase of Mycobacterium fortuitum D316 to study potentially poor substrates and inhibitory beta-lactam compounds. Antimicrobial Agents and Chemotherapy, 1994, 38, 1608-1614.	1.4	44
97	Transcription and expression analysis, using lacZ and phoA gene fusions, of Mycobacterium fortuitum β -lactamase genes cloned from a natural isolate and a high-level β -lactamase producer. Molecular Microbiology, 1994, 12, 491-504.	1.2	104
98	Activity of Antimicrobial Drugs Evaluated by Agar Dilution and Radiometric Methods against Strains of Nocardia asteroides Isolated in Italy from Immunocompromised Patients. Journal of Chemotherapy, 1994, 6, 29-34.	0.7	12
99	Resistance to beta-lactams in Mycobacterium fortuitum. Antimicrobial Agents and Chemotherapy, 1992, 36, 1068-1072.	1.4	25
100	Activity of Antimicrobial Agents Against Mycobacterium avium-intracellulare Complex (MAC) Strains Isolated in Italy from AIDS-Patients. Zentralblatt Fur Bakteriologie: International Journal of Medical Microbiology, 1992, 276, 512-520.	0.5	6
101	In Vitro Activity of Clarithromycin Alone or in Combination with Other Antimicrobial Agents against Mycobacterium avium-intracellulare Complex Strains Isolated from AIDS Patients. Journal of Chemotherapy, 1991, 3, 357-362.	0.7	9
102	Beta-lactamase of Mycobacterium fortuitum: kinetics of production and relationship with resistance to beta-lactam antibiotics. Antimicrobial Agents and Chemotherapy, 1991, 35, 1760-1764.	1.4	18
103	Characterization of a β -lactamase produced in Mycobacterium fortuitum D316. Biochemical Journal, 1990, 271, 729-734.	1.7	33
104	Inhibitors and Inactivators of Beta-Lactamase from Mycobacterium fortuitum. Journal of Chemotherapy, 1989, 1, 293-297.	0.7	6
105	Induction of Mycobacterium avium proteins upon infection of human macrophages. , 0, , 279-287.		0